Z
inc is an essential trace element, which is absorbed in the small intestine and serves as a cofactor for numerous enzymes involved in growth, immune function, and tissue repair. 1, 2 Zinc levels are often low in patients with chronic diarrhea or malabsorptive disorders. Similarly, zinc deficiency is common in patients with inflammatory bowel disease (IBD) during disease and in remission, with a prevalence ranging from 15% to 40%. [3] [4] [5] [6] Preclinical data and human studies support that zinc deficiency may contribute to mucosal inflammation in patients with IBD. In animal models, zinc deficiency exacerbates colitis and potentiates production of proinflammatory cytokines, including tumor necrosis factor a. 7, 8 Furthermore, previous work indicates that a low zinc diet in healthy volunteers results in a decrease in the Th1 cytokines, interferon g, and interleukin-2, as well as diminished lytic activity of natural killer cells. 2 In addition to the impact of zinc on immune function, studies involving both animal models of colitis and patients with Crohn's disease (CD) have demonstrated improvement in mucosal permeability with zinc supplementation. 9, 10 Despite these data supporting the role of zinc deficiency in active mucosal inflammation and epithelial barrier function, there are no studies examining clinical outcomes in patients with IBD who are zinc deficient. As such, we sought to test the hypothesis that patients with IBD deficient in zinc would have poor clinical outcomes.
METHODS

Study Population
The University of Chicago Medicine Digestive Diseases Center maintains an Institutional Review Board-approved prospectively collected registry of patients with IBD. We identified patients seen between 2000 and 2015 who had at least 2 serum zinc concentrations performed as part of their standard clinical care and at least 3 months of subsequent follow-up.
ICP optical emission spectrometry (ICP-OES). Zinc concentrations were defined as either normal if $0.66 mg/mL or deficient if ,0.66 mg/mL according to laboratory reference values.
Variables and Outcomes
Age at index zinc measurement, age at diagnosis of IBD, sex, race, smoking status, previous Crohn's-related small bowel resections, duration of disease at the time of index zinc measurement, and C-reactive protein (CRP) and albumin levels measured concurrently with zinc were obtained through abstraction from the electronic medical record. Using the prescription function of the electronic medical record, we ascertained if a patient was taking IBD-related medications including aminosalicylates, immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), and anti-tumor necrosis factor-a monoclonal antibodies at any time point.
Outcomes after index zinc measurement were compared between patients who were zinc deficient and those with normal zinc levels. In subjects who were zinc deficient on index measurement, outcomes were also assessed after a second zinc measurement and compared between subjects who corrected serum zinc levels within 12 months and those who remained deficient. Primary outcomes included IBD-related hospitalizations, IBD-related surgeries (surgical resection with or without creation of a stoma or ileoanal pouch), or IBD-related complications (including malnutrition, dehydration, anemia, hemorrhage, intestinal obstruction, fistula, abscess, and colonic stricture) using the appropriate procedure Current Procedural Terminology (CPT) codes for surgical procedures or complications. CPT 
Statistical Analysis
Statistical analyses were performed using Stata v14 (College Station, TX). Comparisons between groups were made using the chi-squared test for categorical variables and Wilcoxon rank-sum test or Student's t test for continuous variables. For each of the 3 IBD-related outcomes (at least 1 IBD-related hospitalization, surgery, or complication), univariate logistic regression models were fit to examine associations with covariates of interest for patients with either CD or ulcerative colitis (UC) Covariates with P , 0.15 in either the CD or UC univariate analysis were included in multivariate analyses to examine the impact of low zinc on the outcomes of interest. To account for the potential impact of differential follow-up on outcomes, duration of followup was included in the multivariate models. Estimated average probabilities from the multivariate models were plotted. Similar analyses were performed for those with low zinc levels comparing subjects who corrected their zinc level within 12 months with those who remained zinc deficient.
ETHICAL CONSIDERATIONS
The study was approved by the Institutional Review Board at the University of Chicago (IRB # 15-1175).
RESULTS
Study Population
Seven hundred seventy-three patients with CD and 223 patients with UC were included in the analysis. Median length of follow-up was 3 years for the entire cohort (interquartile range: 2-6 yrs). In subjects with CD, female sex (P ¼ 0.03), race (P ¼ 0.002), lower mean serum albumin level (P , 0.001), higher median CRP concentration (P , 0.001), and previous small bowel surgery (P ¼ 0.05) were associated with serum zinc deficiency. The only baseline variables associated with serum zinc deficiency in patients with UC were albumin (P , 0.001) and CRP levels (P , 0.001). Medication usage, age, disease duration, and smoking status were not associated with zinc deficiency in either group of patients (Table 1) .
Zinc Deficiency is Associated With an Increased Rate of IBD-related Hospitalizations, Surgeries, and Complications
Overall, 31% of patients in the cohort had at least one IBDrelated hospitalization, 21% had an IBD-related surgery, and 64% had an IBD-related complication in the follow-up after index zinc measurement. After controlling for covariates that were demonstrated to have an association with the outcomes of interest in a univariate analysis (see Tables 1-3 , Supplemental Digital Content 1, http://links.lww.com/IBD/B417), CD subjects with zinc deficiency had greater odds of having a CD-related hospitalization (P ¼ 0.04), operation (P ¼ 0.001), or complication (P ¼ 0.03) compared with those who had normal serum zinc levels. Likewise, patients with UC with zinc deficiency had greater odds of having a UC-related hospitalization (P ¼ 0.03) and demonstrated a trend toward significantly increased diseaserelated complications (P ¼ 0.07) compared with those with normal zinc concentrations. There was not an association with subsequent operations (P ¼ 0.3) following a diagnosis of zinc deficiency in patients with UC (Table 2) .
When analyzing the impact of serum zinc deficiency on the location of surgical operations in the bowel, there was an association between zinc deficiency in CD and subsequent small bowel (P ¼ 0.007) as well as large bowel (P ¼ 0.03) operations. In a similar analysis in patients with UC, no association was observed between low zinc levels and subsequent small bowel surgery (P ¼ 0.3), although zinc deficiency trended toward a significant association with future colon surgery (P ¼ 0.07) (see Table 4 , Supplemental Digital Content 2, http://links.lww.com/ IBD/B418).
We also investigated the influence of serum zinc deficiency on the most common IBD-related complications: malnutrition, anemia, hemorrhage, and fistula. Malnutrition and anemia were diagnosed more frequently after a diagnosis of zinc deficiency in patients with CD. Among patients with CD, there was no association between low zinc concentrations and future bowel hemorrhage or a diagnosis of a new and established abdominal or perianal fistula. In subjects with UC, there was not a significant association between zinc deficiency and any of the specific disease-related complications investigated (see Table 5 , Supplemental Digital Content 3, http://links. lww.com/IBD/B419). Albumin levels were available at the time of index zinc measurement in 678 subjects with CD (normal zinc, n ¼ 390; low zinc, n ¼ 288) and 194 subjects with UC (normal zinc, n ¼ 118, low zinc, n ¼ 76).
b CRP values were available at the time of index zinc measurement in 578 subjects with CD (normal zinc, n ¼ 333; low zinc, n ¼ 245) and 148 subjects with UC (normal zinc, n ¼ 88, low zinc, n ¼ 60).
c CD extent (L classification) was available in 736 subjects (normal zinc, n ¼ 413; low zinc, n ¼ 323). Disease phenotype (B classification) was available in 621 subjects with CD (normal zinc, n ¼ 361; low zinc, n ¼ 260). TNF, tumor necrosis factor.
Normalization of Serum Zinc Concentration is Associated with Improved Clinical Outcomes
In patients who were zinc deficient at the time of index zinc measurement, outcomes were also compared between those who corrected their zinc concentration within 12 months and those who remained zinc deficient. Normalization was confirmed by at least 2 measurements in all patients. In patients with CD, normalization of zinc concentrations (n ¼ 76) was associated with a decrease in hospitalizations (P , 0.001), surgeries (P ¼ 0.001), and disease-related complications (P ¼ 0.001) compared with subjects who remained zinc deficient (n ¼ 156). Similarly, patients with UC who corrected deficient zinc concentration (n ¼ 18) had fewer hospitalizations (P ¼ 0.01) and diseaserelated complications (P ¼ 0.01) compared with those who remained zinc deficient (n ¼ 74). Correction of zinc deficiency, in patients with UC, however, did not have a significant association with subsequent surgeries (Table 3) .
DISCUSSION
In this large single-center cohort of patients with IBD, we demonstrate that serum zinc deficiency is associated with diseaserelated morbidity. This is reflected in an increase in hospitalizations, operations, and disease-associated complications in patients with CD who were zinc deficient compared with those with normal zinc levels. Although patients with UC demonstrated a similar odds ratio for each outcome, only hospitalizations reached statistical significance, likely reflecting the smaller sample size of patients with UC included in this analysis. These outcomes improved in patients with both CD and UC who were zinc deficient and had normalization of zinc levels compared with those who remained deficient.
Zinc deficiency in patients with IBD may result from poor oral intake, decreased absorption, or previous small bowel resection and is thought to contribute to mucosal inflammation. [3] [4] [5] [6] Preclinical models and human translational studies have demonstrated that low serum zinc concentrations may exacerbate inflammation through disruption of epithelial barrier function, impaired mucosal immunity, and increasing proinflammatory cytokines. 2, 9, [11] [12] [13] [14] Lending support to the outcomes of these mechanistic investigations, a recently published prospective study examining 17,776 healthy women who were followed over a 26-year period reported that dietary zinc supplementation was inversely associated with the risk of being diagnosed with CD. 15 As plasma and serum zinc concentrations are widely used clinically, we chose serum zinc concentrations for a comparison in this analysis given the availability of data in this patient population and its clinical relevance. Peripheral zinc concentrations are maintained by a balance of proximal gastrointestinal tract intake, fecal losses, and slow release from tissue stores. 16 Although it is hypothesized that zinc within cellular metallothionein located in solid organs may be a better marker of total body stores of zinc, animal and human data have demonstrated that Using a multivariable logistic regression model, development of at least 1 IBD-related hospitalization, IBD-related surgery, or IBD-related complication after index zinc measurement was compared between subjects who were zinc deficient and those with normal zinc concentrations. Covariables included in the multivariate logistic regression model were those that had a P , 0.15 in a univariate analysis. For hospitalizations, the covariates included in the logistic regression model were race, use of an anti-tumor necrosis factor or immunomodulator agent, categorical albumin level (missing versus ,3 versus .3), CRP category (missing versus #10 versus .10), and follow-up duration. For surgeries, the covariates analyzed were race, use of anti-tumor necrosis factor medications, disease duration, categorical albumin level, CRP category, follow-up duration, and previous small bowel resection for patients with CD. Variables analyzed to assess disease complications in the logistic regression model were race, use of anti-tumor necrosis factor medications, smoking, categorical albumin levels, CRP category, and follow-up duration. CI, confidence interval; OR, odds ratio. Using a logistic regression model, development of at least 1 IBD-related hospitalization, IBD-related surgery, or IBD-related complication were compared between those who had normalization of zinc deficiency within 12 months of index zinc measurement and those who remained deficient. Odds ratios and P values for patients with CD were calculated using a multivariable model controlling for covariates. For hospitalizations, the covariates included in the model were race, use of anti-tumor necrosis factor or immunomodulatory agent, categorical albumin level, and follow-up duration. For surgeries, the covariates included were race, use of anti-tumor necrosis factor medications, duration of disease, categorical albumin level, and follow-up duration. For Crohn's-related complications, included factors in the model were race, use of anti-tumor necrosis factor medications, smoking, categorical albumin level, and follow-up duration. Odds ratios and P values for patients with UC were calculated using a univariate logistic regression model, given the few number of patients in the cohort who had correction of zinc deficiency (n ¼ 18). CI, confidence interval; OR, odds ratio.
plasma zinc is as useful and accurate as tissue concentrations of zinc. 17, 18 Furthermore, plasma zinc concentrations may reflect zinc status better during states of acute zinc depletion because of the slow equilibration of total zinc pools. 16 The results of our study further endorse the hypothesis that zinc deficiency may contribute to disease activity in patients with IBD. To our knowledge, this is the first report to examine outcomes after a diagnosis of serum zinc deficiency or after correction of serum zinc deficiency in a cohort of patients with IBD. The major strength of this study is the ability to capture outcomes in a large cohort of patients with IBD followed longitudinally. Furthermore, we were able to control for patient-specific factors known to be associated with poor outcomes in IBD, including age, sex, race, elevated CRP, use of immunomodulators or biologics, smoking status, previous resections and Montreal score in patients with CD, and disease duration. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In addition to controlling for these variables, our analyses also took into account serum albumin levels. Seventy-five to 98% of serum zinc is bound to proteins, including albumin and alpha-2 macroglobulin. 29 While alpha-2 macroglobulin is generally stable, albumin levels may fluctuate in the setting of malnutrition, surgery, or active bowel inflammation. [30] [31] [32] [33] Therefore, demonstrating that the impact of zinc on clinical outcomes occurs independent of serum albumin levels is important and not performed routinely in clinical studies focused on zinc.
Although we did control for both CRP and albumin levels, which may reflect mucosal inflammation, a major limitation of this study is that we were unable to directly assess disease activity at the time of zinc measurement. As such, we cannot conclude with our study design whether the poor outcomes associated with zinc deficiency occur independently of more severe mucosal inflammation at baseline. Furthermore, those with more severe disease activity may have been more likely to have a zinc level drawn, repeated, and have closer follow-up which could have biased the recording of outcomes, particularly disease-associated complications. In addition, we were unable to analyze the impact of dietary intervention or zinc supplementation on peripheral zinc concentrations in this cohort of study patients. Nonetheless, we do believe that our "real world" assessment of these measures and outcomes has clinical value.
In conclusion, zinc deficiency in IBD is associated with the development of disease-related complications, and subsequent normalization of zinc levels is associated with improved outcomes. These results support the practice of close monitoring of zinc concentrations in patients with active IBD and adequate replacement in those who are deficient. Prospective intervention studies are needed to better understand the pathogenetic mechanisms and potential benefit of zinc replacement therapy on mucosal inflammation in this population.
